Experienced in Autoimmune Hemolytic Anemia

Dr. Charles A. Schiffer

Oncology | Hematology
4100 John R St, 
Detroit, MI 
Experienced in Autoimmune Hemolytic Anemia
4100 John R St, 
Detroit, MI 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Charles Schiffer is an Oncologist and a Hematologist in Detroit, Michigan. Dr. Schiffer is rated as an Experienced provider by MediFind in the treatment of Autoimmune Hemolytic Anemia. His top areas of expertise are Chronic Myelogenous Leukemia (CML), Acute Myeloid Leukemia (AML), Leukemia, Hairy Cell Leukemia (HCL), and Bone Marrow Transplant.

His clinical research consists of co-authoring 80 peer reviewed articles and participating in 11 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Oncology
Hematology
Licenses
Internal Medicine in MI
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
McLaren Health
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO

Locations

4100 John R St, Detroit, MI 48201

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

11 Clinical Trials

A Phase II Study of IRD (Ixazomib, Lenalidomide, & Dexamethasone) for Consolidation Therapy Post Autologous Stem Cell Transplantation Followed by Maintenance Ixazomib or Lenalidomide for Multiple Myeloma
A Phase II Study of IRD (Ixazomib, Lenalidomide, & Dexamethasone) for Consolidation Therapy Post Autologous Stem Cell Transplantation Followed by Maintenance Ixazomib or Lenalidomide for Multiple Myeloma
Enrollment Status: Active_not_recruiting
Publish Date: October 07, 2025
Intervention Type: Drug, Biological
Study Drugs: Ixazomib, Lenalidomide, Dexamethasone
Study Phase: Phase 2
A Phase II Study Evaluating Safety and Efficacy of Polatuzumab Vedotin in Combination With Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone in Patients With Previously Untreated Double and Triple Hit Lymphoma, Double Expressor Lymphoma and High-Grade B Cell Lymphoma
A Phase II Study Evaluating Safety and Efficacy of Polatuzumab Vedotin in Combination With Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone in Patients With Previously Untreated Double and Triple Hit Lymphoma, Double Expressor Lymphoma and High-Grade B Cell Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: September 29, 2025
Intervention Type: Drug, Biological
Study Drugs: Prednisone, Prednisolone, Methylprednisolone, Rituximab, Polatuzumab Vedotin, Cyclophosphamide, Doxorubicin Hydrochloride
Study Phase: Phase 2
A Phase 1b/2 Investigator Initiated Study of RCHOP in Combination With Selinexor (KPT-330) in B Cell Non-Hodgkin's Lymphoma
A Phase 1b/2 Investigator Initiated Study of RCHOP in Combination With Selinexor (KPT-330) in B Cell Non-Hodgkin's Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: September 29, 2025
Intervention Type: Drug
Study Drug: Selinexor
Study Phase: Phase 1/Phase 2
A Multicenter Phase 2 Study of the Bruton's Tyrosine Kinase Inhibitor PCI-32765 (Ibrutinib) for Treatment of Relapsed Hairy Cell Leukemia
A Multicenter Phase 2 Study of the Bruton's Tyrosine Kinase Inhibitor PCI-32765 (Ibrutinib) for Treatment of Relapsed Hairy Cell Leukemia
Enrollment Status: Active_not_recruiting
Publish Date: September 17, 2025
Intervention Type: Procedure, Drug
Study Drug: Ibrutinib
Study Phase: Phase 2
A Randomized, Open-label, Phase 2 Trial of Ponatinib in Patients With Resistant Chronic Phase Chronic Myeloid Leukemia to Characterize the Efficacy and Safety of a Range of Doses
A Randomized, Open-label, Phase 2 Trial of Ponatinib in Patients With Resistant Chronic Phase Chronic Myeloid Leukemia to Characterize the Efficacy and Safety of a Range of Doses
Enrollment Status: Completed
Publish Date: May 01, 2025
Intervention Type: Drug
Study Drug: Ponatinib
Study Phase: Phase 2
A Phase II Multicenter Single Arm Study to Evaluate the Efficacy and Safety of Single Agent Bruton's Tyrosine Kinase Inhibitor, Ibrutinib, in Patients With Relapsed Refractory Classical Hodgkin's Lymphoma
A Phase II Multicenter Single Arm Study to Evaluate the Efficacy and Safety of Single Agent Bruton's Tyrosine Kinase Inhibitor, Ibrutinib, in Patients With Relapsed Refractory Classical Hodgkin's Lymphoma
Enrollment Status: Completed
Publish Date: February 17, 2025
Intervention Type: Drug, Other
Study Drug: Ibrutinib
Study Phase: Phase 2
A Phase 1 / 2 Study to Evaluate the Safety and Tolerability of Adoptively Transferred Autologous T Cells in Patients With Relapsed Refractory Multiple Myeloma
A Phase 1 / 2 Study to Evaluate the Safety and Tolerability of Adoptively Transferred Autologous T Cells in Patients With Relapsed Refractory Multiple Myeloma
Enrollment Status: Suspended
Publish Date: January 16, 2024
Intervention Type: Biological
Study Drug: NEXI-002 T Cells
Study Phase: Phase 1/Phase 2
A Phase 2 Trial of the Discussion of Cost (DISCO) App as an Intervention to Improve Financial Outcomes in Hematologic Cancer Patients
A Phase 2 Trial of the Discussion of Cost (DISCO) App as an Intervention to Improve Financial Outcomes in Hematologic Cancer Patients
Enrollment Status: Completed
Publish Date: May 03, 2023
Intervention Type: Behavioral
Study Phase: Not Applicable
A Randomized Phase 2 Trial of Lenalidomide/ Dexamethasone/ Elotuzumab +/- Cyclophosphamide Followed by Lenalidomide/ Dexamethasone/Elotuzumab Maintenance as Second-Line Therapy for Patients With Relapsed AL Amyloidosis
A Randomized Phase 2 Trial of Lenalidomide/ Dexamethasone/ Elotuzumab +/- Cyclophosphamide Followed by Lenalidomide/ Dexamethasone/Elotuzumab Maintenance as Second-Line Therapy for Patients With Relapsed AL Amyloidosis
Enrollment Status: Unknown
Publish Date: January 25, 2023
Intervention Type: Drug, Other, Biological
Study Drugs: Cyclophosphamide, Dexamethasone, Elotuzumab, Lenalidomide
Study Phase: Phase 2
Phase I Study of Dasatinib in Recipients of Allogeneic Stem Cell Transplantation for Hematologic Malignancies.
Phase I Study of Dasatinib in Recipients of Allogeneic Stem Cell Transplantation for Hematologic Malignancies.
Enrollment Status: Terminated
Publish Date: December 17, 2020
Intervention Type: Other, Drug
Study Phase: Phase 1
Phase I Study of Dasatinib in Recipients of Autologous Stem Cell Transplantation for Hematologic Malignancies.
Phase I Study of Dasatinib in Recipients of Autologous Stem Cell Transplantation for Hematologic Malignancies.
Enrollment Status: Terminated
Publish Date: March 16, 2020
Intervention Type: Drug
Study Phase: Phase 1
View 10 Less Clinical Trials

80 Total Publications

2025 European LeukemiaNet recommendations for the management of chronic myeloid leukemia.
2025 European LeukemiaNet recommendations for the management of chronic myeloid leukemia.
Journal: Leukemia
Published: May 29, 2025
Similar Doctors
Distinguished in Autoimmune Hemolytic Anemia
Dr. Lyle S. Goldman
Hematology Oncology | Hematology | Oncology
Distinguished in Autoimmune Hemolytic Anemia
Dr. Lyle S. Goldman
Hematology Oncology | Hematology | Oncology

Ascension St John Hospital

31500 Telegraph Rd, Suite 225, 
Bingham Farms, MI 
 (16.4 miles away)
248-552-0620
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Lyle Goldman is a Hematologist Oncology specialist and a Hematologist in Bingham Farms, Michigan. Dr. Goldman is rated as a Distinguished provider by MediFind in the treatment of Autoimmune Hemolytic Anemia. His top areas of expertise are Gallbladder Adenocarcinoma, Autoimmune Hemolytic Anemia, Colorectal Cancer, Bone Marrow Aspiration, and Endoscopy. Dr. Goldman is currently accepting new patients.

Distinguished in Autoimmune Hemolytic Anemia
Dr. Paula L. Bockenstedt
Hematology
Distinguished in Autoimmune Hemolytic Anemia
Dr. Paula L. Bockenstedt
Hematology
1500 East Medical Center Dr, B1 Floor Cancer & Geriatrics Ctr Recp B, 
Ann Arbor, MI 
 (34.7 miles away)
734-936-6000
Languages Spoken:
English
See accepted insurances

Paula Bockenstedt is a Hematologist in Ann Arbor, Michigan. Dr. Bockenstedt is rated as a Distinguished provider by MediFind in the treatment of Autoimmune Hemolytic Anemia. Her top areas of expertise are Antiphospholipid Syndrome, Hemophilia A, Hemophilic Arthropathy, and Venous Thromboembolism (VTE).

Advanced in Autoimmune Hemolytic Anemia
Dr. Asra Ahmed
Hematology
Advanced in Autoimmune Hemolytic Anemia
Dr. Asra Ahmed
Hematology

Regents Of The University Of Michigan

1500 E Medical Ctr Dr, 
Ann Arbor, MI 
 (34.7 miles away)
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Asra Ahmed is a Hematologist in Ann Arbor, Michigan. Dr. Ahmed is rated as a Distinguished provider by MediFind in the treatment of Autoimmune Hemolytic Anemia. Her top areas of expertise are Reticulohistiocytoma, Histiocytosis, Non-Langerhans-Cell Histiocytosis, Rosai-Dorfman Disease, and Bone Marrow Aspiration.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Schiffer's expertise for a condition
ConditionClose
View All 15 Advanced Conditions
View All 37 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile